---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006757"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:39:05.220128+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen reports Q4/FY2024: JELMYTO rev $90.4M; net loss $126.9M; guides FY2025 rev $94-98M

## Summary
- UGN-102 NDA under FDA review; PDUFA June 13, 2025; 18-month DOR 80.6% in Phase 3 ENVISION trial.
- JELMYTO net product revenue $90.4M in FY2024, up 9% YoY; underlying demand revenue grew 12% (FY) and 15% (Q4).
- Net loss Q4 2024 $37.5M ($0.80/share) vs $26.0M ($0.72/share) in Q4 2023; FY net loss $126.9M ($2.96/share) vs $102.2M ($3.55/share).
- FY2025 guidance: JELMYTO revenue $94-98M; operating expenses $215-225M (incl. $11-14M share-based comp).
- Cash, equivalents and marketable securities $241.7M at Dec 31, 2024, up from $141.5M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001437749-25-006757
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/0001437749-25-006757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/urgn20250304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006757
- JSON: https://secwatch.observer/filing/0001437749-25-006757.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.